CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-16 | Rosenberg Anthony Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-09-16 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-09-16 | GADICKE ANSBERT Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-09-16 | Jovan-Embiricos Morana Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-09-16 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −3,124 | $29.06 | $91K | 7,648,268 |
| 2021-09-16 | GADICKE ANSBERT Director | Sale | −432 | $29.06 | $13K | 244,551 |
| 2021-09-16 | GADICKE ANSBERT Director | Sale | −3,124 | $29.06 | $91K | 7,648,268 |
| 2021-09-15 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −6,425 | $29.16 | $187K | 7,651,392 |
| 2021-09-15 | GADICKE ANSBERT Director | Sale | −888 | $29.16 | $26K | 244,983 |
| 2021-09-15 | GADICKE ANSBERT Director | Sale | −6,425 | $29.16 | $187K | 7,651,392 |
| 2021-09-14 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −7,106 | $29.17 | $207K | 7,657,817 |
| 2021-09-14 | GADICKE ANSBERT Director | Sale | −982 | $29.17 | $29K | 245,871 |
| 2021-09-14 | GADICKE ANSBERT Director | Sale | −7,106 | $29.17 | $207K | 7,657,817 |
| 2021-09-13 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −3,595 | $29.10 | $105K | 7,664,923 |
| 2021-09-13 | GADICKE ANSBERT Director | Sale | −497 | $29.10 | $14K | 246,853 |
| 2021-09-13 | GADICKE ANSBERT Director | Sale | −3,595 | $29.10 | $105K | 7,664,923 |
| 2021-09-10 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −5,931 | $29.04 | $172K | 7,668,518 |
| 2021-09-10 | GADICKE ANSBERT Director | Sale | −820 | $29.04 | $24K | 247,350 |
| 2021-09-10 | GADICKE ANSBERT Director | Sale | −5,931 | $29.04 | $172K | 7,668,518 |
| 2021-09-09 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −13,727 | $29.35 | $403K | 7,674,449 |
Page 16 of 23 · 446 trades